Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 1/20 | 0.61 |
| ▸ | GAA | P10253 | 1/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.61 |
| ▸ | CA12 | O43570 | 1/20 | 0.60 |
| ▸ | CA1 | P00915 | 1/20 | 0.60 |
| ▸ | CA2 | P00918 | 1/20 | 0.60 |
| ▸ | CA7 | P43166 | 1/20 | 0.60 |
| ▸ | CA9 | Q16790 | 1/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.60 |
| ▸ | EPHX2 | P34913 | 4/20 | 0.56 |
| ▸ | NPC1 | O15118 | 1/20 | 0.56 |
| ▸ | RAB9A | P51151 | 1/20 | 0.56 |
| ▸ | ACACB | O00763 | 1/20 | 0.54 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3569060 | 0.88 | LTA4H (0.67) | LTA4HGAASMN1; SMN2CA12CA1 | |
| SCHEMBL10897064 | 0.86 | ALDH1A1 (0.67) | LTA4HGAASMN1; SMN2CA12CA1 | |
| SCHEMBL14987027 | 0.85 | KDM4E (0.62) | LTA4HSMN1; SMN2ALDH1A1KDM4EEPHX2 | |
| SCHEMBL28502559 | 0.84 | NPC1 (0.67) | LTA4HGAASMN1; SMN2CA12CA1 | |
| SCHEMBL7400266 | 0.84 | GAA (0.62) | LTA4HGAASMN1; SMN2CA12CA1 | |
| SCHEMBL3007594 | 0.83 | GAA (0.71) | LTA4HGAASMN1; SMN2CA12CA1 | |
| SCHEMBL15160748 | 0.83 | GAA (0.60) | LTA4HGAASMN1; SMN2CA12CA1 | |
| SCHEMBL10377 | 0.83 | NPC1 (0.58) | LTA4HGAASMN1; SMN2CA12CA1 | |
| Hydrochloric Acid SCHEMBL14742324 | 0.82 | GAA (0.70) | GAASMN1; SMN2CA12CA1CA2 | |
| SCHEMBL5510481 | 0.81 | AOC3 (0.55) | CA2ALDH1A1KDM4EEPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9642847-B2 | Combinational compositions and methods for treatment of cancer | ARQULE, INC. (US) | 2017-05-09 | — | — | US | disclosed |
| US-20160355515-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF CANCER | ARQULE, INC. | 2016-12-08 | — | — | US | disclosed |
| US-9447088-B2 | Compositions and methods for treatment of cancer | ARQULE, INC. (US) | 2016-09-20 | — | — | US | disclosed |
| US-20150328208-A1 | COMBINATIONAL COMPOSITIONS AND METHODS FOR TREATMENT OF CANCER | ARQULE, INC. | 2015-11-19 | — | — | US | disclosed |
| US-20140200199-A1 | Compositions and Methods for Treatment of Cancer | ARQULE, INC. | 2014-07-17 | — | — | US | disclosed |
| US-8754078-B2 | Compositions and methods for treatment of cancer | ARQULE, INC. (US) | 2014-06-17 | — | — | US | disclosed |
| US-20130150310-A1 | Compositions and Methods for Treatment of Cancer | ARQULE, INC. (US) | 2013-06-13 | — | — | US | disclosed |
| EP-2396003-B1 | A composition comprising (-)-trans-3-(5,6-dihydro-4h-pyrrolo [3,2,1-ij] quinolin-1-yl)-4-(1h-indol-3-yl) pyrrolidine-2, 5-dione in combination with sorafenib, sunitinib or erlotinib | ARQULE INC (US) | 2013-04-17 | — | — | EP | disclosed |
| US-8377927-B2 | Compositions and methods for treatment of cancer | ARQULE, INC. (US) | 2013-02-19 | — | — | US | disclosed |
| EP-2289892-B1 | Maleimide derivatives, pharmaceutical compositions amd methods for treatment of cancer | ARQULE INC (US) | 2012-08-22 | — | — | EP | disclosed |
| EP-2396003-A2 | A COMPOSITION COMPRISING (-)-TRANS-3-(5,6-DIHYDRO-4H-PYRROLO [3,2,1-IJ] QUINOLIN-1-YL)-4-(1H-INDOL-3-YL) PYRROLIDINE-2, 5-DIONE IN COMBINATION WITH A SECOND ANTI-PROLIFERATIVE AGENT, | ArQule, Inc. (US) | 2011-12-21 | — | — | EP | disclosed |
| EP-2289892-A1 | Maleimide derivatives, pharmaceutical compositions amd methods for treatment of cancer | ArQule, Inc. (US) | 2011-03-02 | — | — | EP | disclosed |
| US-20100297075-A1 | COMBINATIONAL COMPOSITIONS AND METHODS FOR TREATMENT OF CANCER | ARQULE, INC. (US) | 2010-11-25 | — | — | US | disclosed |
| EP-1846406-B1 | MALEIMIDE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR TREATMENT OF CANCER | ARQULE INC (US) | 2010-11-03 | — | — | EP | disclosed |
| US-20100221251-A1 | Compositions and Methods for Treatment of Cancer | ARQULE, INC. (US) | 2010-09-02 | — | — | US | disclosed |
| WO-2010093789-A2 | COMBINATIONAL COMPOSITIONS AND METHODS FOR TREATMENT OF CANCER | ARQULE, INC. (US) | 2010-08-19 | — | — | WO | disclosed |
| US-7713969-B2 | (+)-cis-3-(5,6-dihydro-4H-pyrrolo[3,2,1-ij]quinolin-1yl)-4(1H-indol-3-yl) pyrrolidine-2,5-dione; lung, colon, breast, pancreatic, prostate cancers, chronic myelogenous leukemia, melanoma, or ovarian cancer | ARQULE, INC. (US) | 2010-05-11 | — | — | US | disclosed |
| EP-1846406-A1 | MALEIMIDE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR TREATMENT OF CANCER | ArQule, Inc. (US) | 2007-10-24 | — | — | EP | disclosed |
| US-20060223760-A1 | (+)-cis-3-(5,6-dihydro-4H-pyrrolo[3,2,1-ij]quinolin-1yl)-4(1H-indol-3-yl) pyrrolidine-2,5-dione; lung, colon, breast, pancreatic, prostate cancers, chronic myelogenous leukemia, melanoma, or ovarian cancer | ARQULE, INC. | 2006-10-05 | — | — | US | disclosed |
| WO-2006086484-A1 | MELEIMIDE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR TREATMENT OF CANCER | ARQULE, INC. (US) | 2006-08-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100297075-A1 | COMBINATIONAL COMPOSITIONS AND METHODS FOR TREATMENT OF CANCER | TP53, MKI67, POLI | LTA4H 3886/4885GAA 2298/4885SMN1; SMN2 1867/4885 |
| US-20150328208-A1 | COMBINATIONAL COMPOSITIONS AND METHODS FOR TREATMENT OF CANCER | TP53, MKI67, POLI | LTA4H 3886/4885GAA 2298/4885SMN1; SMN2 1867/4885 |
| US-20140200199-A1 | Compositions and Methods for Treatment of Cancer | MKI67, NUP205, TP53 | LTA4H 3018/4885GAA 1789/4885SMN1; SMN2 2196/4885 |
| US-20160355515-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF CANCER | MKI67, NUP205, TP53 | LTA4H 3018/4885GAA 1789/4885SMN1; SMN2 2196/4885 |
| US-20100221251-A1 | Compositions and Methods for Treatment of Cancer | PDCD5, TP53, NUP205 | LTA4H 3463/4885GAA 1339/4885SMN1; SMN2 2087/4885 |
| US-20130150310-A1 | Compositions and Methods for Treatment of Cancer | MKI67, NUP205, TP53 | LTA4H 3018/4885GAA 1789/4885SMN1; SMN2 2196/4885 |
| US-20060223760-A1 | (+)-cis-3-(5,6-dihydro-4H-pyrrolo[3,2,1-ij]quinolin-1yl)-4(1H-indol-3-yl) pyrrolidine-2,5-dione; lung, colon, breast, pancreatic, prostate cancers, chronic myelogenous leukemia, melanoma, or ovarian cancer | MCL1, BRCA1, IDO1 | LTA4H 2319/4885GAA 3764/4885SMN1; SMN2 2298/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.